Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version

Bimal Bhindi; Ronald Kool; Girish S. Kulkarni; D. Robert Siemens; Armen G. Aprikian; Rodney H. Breau; Fadi Brimo; Adrian Fairey; Christopher French; Nawar Hanna; Jonathan I. Izawa; Louis Lacombe; Victor McPherson; Ricardo A. Rendon; Bobby Shayegan; Alan I. So; Alexandre R. Zlotta; Peter C. Black; Wassim Kassouf

doi:10.5489/CUAJ.7487

Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version

Bimal Bhindi, Ronald Kool, Girish S. Kulkarni, D. Robert Siemens, Armen G. Aprikian, Rodney H. Breau, Fadi Brimo, Adrian Fairey, Christopher French, Nawar Hanna, Jonathan I. Izawa, Louis Lacombe, Victor McPherson, Ricardo A. Rendon, Bobby Shayegan, Alan I. So, Alexandre R. Zlotta, Peter C. Black, Wassim Kassouf

科研成果: 期刊稿件 › 文献综述 › 同行评审

9 引用（Scopus）

源语言	英语
页（从-至）	230-239
页数	10
期刊	Journal of the Canadian Urological Association
卷	15
期	8
DOI	https://doi.org/10.5489/CUAJ.7487
出版状态	已出版 - 8月 2021
已对外发布	是

!!!ASJC Scopus Subject Areas

泌尿学

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.5489/CUAJ.7487

其它文件与链接

引用此

Bhindi, B., Kool, R., Kulkarni, G. S., Robert Siemens, D., Aprikian, A. G., Breau, R. H., Brimo, F., Fairey, A., French, C., Hanna, N., Izawa, J. I., Lacombe, L., McPherson, V., Rendon, R. A., Shayegan, B., So, A. I., Zlotta, A. R., Black, P. C., & Kassouf, W. (2021). Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version. Journal of the Canadian Urological Association, 15(8), 230-239. https://doi.org/10.5489/CUAJ.7487

Bhindi, B, Kool, R, Kulkarni, GS, Robert Siemens, D, Aprikian, AG, Breau, RH, Brimo, F, Fairey, A, French, C, Hanna, N, Izawa, JI, Lacombe, L, McPherson, V, Rendon, RA, Shayegan, B, So, AI, Zlotta, AR, Black, PC & Kassouf, W 2021, 'Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version', Journal of the Canadian Urological Association, 卷 15, 号码 8, 页码 230-239. https://doi.org/10.5489/CUAJ.7487

@article{d54232bcadb04a8bb69d2f2cf99193a4,

title = "Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version",

author = "Bimal Bhindi and Ronald Kool and Kulkarni, {Girish S.} and {Robert Siemens}, D. and Aprikian, {Armen G.} and Breau, {Rodney H.} and Fadi Brimo and Adrian Fairey and Christopher French and Nawar Hanna and Izawa, {Jonathan I.} and Louis Lacombe and Victor McPherson and Rendon, {Ricardo A.} and Bobby Shayegan and So, {Alan I.} and Zlotta, {Alexandre R.} and Black, {Peter C.} and Wassim Kassouf",

note = "Funding Information: Competing interests: Dr. Bhindi has been an advisory board member for Bayer and Janssen; and has received speaker honoraria from Merck. Dr. Kulkarni has been an advisory board member for Astellas, Ferring, Janssen, Merck, Roche, and Theralase; has received grants and/or honoraria from Abbvie, Ferring, Sanofi, and TerSera; and has participated in clinical trials supported by Merck, Astra Zeneca, Bristol Myers Squibb, Janssen, and Theralase. Dr. Siemens has participated in clinical trials supported by Astellas, Merck, and Pfizer. Dr. Aprikian has been an advisory board member for Abbvie, Astellas, and Bayer; and has received grants and/or honoraria from Abbvie, Astellas, Bayer, Sanofi, and TerSera. Dr. Hanna has received honoraria from Astellas and Bayer; and has participated in clinical trials supported by Merck. Dr. Izawa has received honoraria from Abbvie. Dr. McPherson has been an advisory board member for Abbvie and TerSera; has received travel funding from TerSera; and has participated in clinical trials supported by Bristol-Myers Squibb and Pfizer. Dr. Rendon has been an advisory board member for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche, and Sanofi; a speakers{\textquoteright} bureau member for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche , and Sanofi; has received grants and/or honoraria from Abbvie, Astellas, Bayer, Ferring, Janssen, and Sanofi; holds investments in Myovant; and has participated in clinical trials supported by Abbvie, Astellas, Bayer, Bavarian Nordic, Ferring, Janssen, Myovant, and Sanofi. Dr. Shayegan has been an advisory board member for AbbVie, Astellas, Bayer, Ferring Janssen, Knight, Merck, Pfizer, Sanofi, and TerSera; and has participated in clinical trials supported by Ipsen, Janssen, Merck, Myovant, and Pfizer. Dr. So has been an advisory board member for Abbvie, Amgen, Astellas, Bayer, Janssen, Ferring, and TerSera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Zlotta has been an advisory board member for AstraZeneca, Ferring, Janssen, Merck, Sanofi, and Verity. Dr. Black has been an advisory board member for AbbVie, Asieris, Astellas, AstraZeneca, Bayer, Biosyent, BMS, EMD-Serono, Ferring, Fergene, H3-Biomedicine, Janssen, Merck, Protara Therapeutics, Roche, Sanofi, and Urogen; a speakers{\textquoteright} bureau member for AbbVie, Biosyent, Ferring, Janssen, Pfizer, and TerSera; has received payment from Bayer and Sanofi; has received grants and/or honoraria from iProgen; holds a patent marketed by Decipher Biosciences; and has participated in clinical trials supported by Astellas, AstraZeneca, BMS, Genentech, Janssen, MDx Health, Pacific Edge, and Therelase. Dr. Kassouf has been an advisory board member for EMD Serono and Pfizer; has received grants and/or honoraria from Abbvie, Astellas, BMS, Ferring, Janssen, Merck, Roche, and Sesen Bio; and has participated in clinical trials supported by Astra Zeneca, BMS, Janssen, Pfizer, Roche, Sesen Bio, and Theralase. No other authors report any competing personal or financial interests related to this work.",

year = "2021",

month = aug,

doi = "10.5489/CUAJ.7487",

language = "English",

volume = "15",

pages = "230--239",

journal = "Journal of the Canadian Urological Association",

issn = "1911-6470",

publisher = "Canadian Medical Association",

number = "8",

}

TY - JOUR

T1 - Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version

AU - Bhindi, Bimal

AU - Kool, Ronald

AU - Kulkarni, Girish S.

AU - Robert Siemens, D.

AU - Aprikian, Armen G.

AU - Breau, Rodney H.

AU - Brimo, Fadi

AU - Fairey, Adrian

AU - French, Christopher

AU - Hanna, Nawar

AU - Izawa, Jonathan I.

AU - Lacombe, Louis

AU - McPherson, Victor

AU - Rendon, Ricardo A.

AU - Shayegan, Bobby

AU - So, Alan I.

AU - Zlotta, Alexandre R.

AU - Black, Peter C.

AU - Kassouf, Wassim

N1 - Funding Information: Competing interests: Dr. Bhindi has been an advisory board member for Bayer and Janssen; and has received speaker honoraria from Merck. Dr. Kulkarni has been an advisory board member for Astellas, Ferring, Janssen, Merck, Roche, and Theralase; has received grants and/or honoraria from Abbvie, Ferring, Sanofi, and TerSera; and has participated in clinical trials supported by Merck, Astra Zeneca, Bristol Myers Squibb, Janssen, and Theralase. Dr. Siemens has participated in clinical trials supported by Astellas, Merck, and Pfizer. Dr. Aprikian has been an advisory board member for Abbvie, Astellas, and Bayer; and has received grants and/or honoraria from Abbvie, Astellas, Bayer, Sanofi, and TerSera. Dr. Hanna has received honoraria from Astellas and Bayer; and has participated in clinical trials supported by Merck. Dr. Izawa has received honoraria from Abbvie. Dr. McPherson has been an advisory board member for Abbvie and TerSera; has received travel funding from TerSera; and has participated in clinical trials supported by Bristol-Myers Squibb and Pfizer. Dr. Rendon has been an advisory board member for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche, and Sanofi; a speakers’ bureau member for Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Ferring, Janssen, Pfizer, Roche , and Sanofi; has received grants and/or honoraria from Abbvie, Astellas, Bayer, Ferring, Janssen, and Sanofi; holds investments in Myovant; and has participated in clinical trials supported by Abbvie, Astellas, Bayer, Bavarian Nordic, Ferring, Janssen, Myovant, and Sanofi. Dr. Shayegan has been an advisory board member for AbbVie, Astellas, Bayer, Ferring Janssen, Knight, Merck, Pfizer, Sanofi, and TerSera; and has participated in clinical trials supported by Ipsen, Janssen, Merck, Myovant, and Pfizer. Dr. So has been an advisory board member for Abbvie, Amgen, Astellas, Bayer, Janssen, Ferring, and TerSera; and has participated in clinical trials supported by Astellas, Ferring, and Janssen. Dr. Zlotta has been an advisory board member for AstraZeneca, Ferring, Janssen, Merck, Sanofi, and Verity. Dr. Black has been an advisory board member for AbbVie, Asieris, Astellas, AstraZeneca, Bayer, Biosyent, BMS, EMD-Serono, Ferring, Fergene, H3-Biomedicine, Janssen, Merck, Protara Therapeutics, Roche, Sanofi, and Urogen; a speakers’ bureau member for AbbVie, Biosyent, Ferring, Janssen, Pfizer, and TerSera; has received payment from Bayer and Sanofi; has received grants and/or honoraria from iProgen; holds a patent marketed by Decipher Biosciences; and has participated in clinical trials supported by Astellas, AstraZeneca, BMS, Genentech, Janssen, MDx Health, Pacific Edge, and Therelase. Dr. Kassouf has been an advisory board member for EMD Serono and Pfizer; has received grants and/or honoraria from Abbvie, Astellas, BMS, Ferring, Janssen, Merck, Roche, and Sesen Bio; and has participated in clinical trials supported by Astra Zeneca, BMS, Janssen, Pfizer, Roche, Sesen Bio, and Theralase. No other authors report any competing personal or financial interests related to this work.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85113959974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113959974&partnerID=8YFLogxK

U2 - 10.5489/CUAJ.7487

DO - 10.5489/CUAJ.7487

M3 - Review article

AN - SCOPUS:85113959974

SN - 1911-6470

VL - 15

SP - 230

EP - 239

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

IS - 8

ER -